Independent But Not Isolated: Shionogi Takes Unusual Approach To Fortified VC Activities
The corporate venture capital fund within the infectious disease-focused Japanese firm says it wants to keep an open mind and to provide long-term support for modalities and technologies that can be an “exciting fit" in 2040.
Scrip - July 30, 2026

Medtronic’s VP Sees Clear Future For Hugo – And Robotic Surgery As A Product Class
Building a surgical robot is hard – even for a company like Medtronic. Rajit Kamal, Medtronic’s VP and Global Leader of Surgical Robotics, explained how the company got to where it has with its Hugo system, and how Medtronic assesses the ever-increasing value of surgical robots to care systems.
Medtech Insight - July 29, 2026

Philips Q2 Profit Masks Flat Underlying Margin As Tariff Refund Does The Heavy Lifting
Philips’ Q2 profit jumped, but almost entirely on a one-off €186m US tariff refund. Stripped out, the company’s underlying margin was roughly flat as inflation and tariffs offset growth — and order intake fell for the first time in six quarters.
Medtech Insight - July 29, 2026

What Medtech Makers Need To Know About The EU’s New Packaging Rules
The EU's PPWR starts binding packaging obligations on Aug. 12, and there's no blanket medtech exemption. Contact-sensitive device packaging escapes recyclability and recycled-content grades, but conformity assessment, substance limits, EPR and labeling apply in full.
Medtech Insight - July 29, 2026

Science Corp. First Commercial Launch Of BCI To Restore Central Vision In Germany, UK
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026

Q&A: Preparing for California’s SB 54 Packaging Law
HBW Insight spoke with Alyssa Dizon of rePurpose Global about the challenges personal care packaging producers face as they work to comply with California's SB 54.
HBW Insight - July 30, 2026

Teva Targets Forty Biosimilars As Generics Growth Stalls
Teva is scaling biosimilars into a major growth driver, targeting nearly 40 products and expecting to exceed its $800m 2027 sales goal as conventional generics remain under pressure.
Generics Bulletin - July 29, 2026

Feeding Frenzy Looms For Bridion Generics After First US Launches
After the expiry of a key US patent protecting Merck & Co’s Bridion blockbuster, the floodgates have opened for generics, allowing launches into a $1.6bn market – but with more than a dozen firms holding ANDA approvals, competition is set to be fierce.
Generics Bulletin - July 29, 2026

Brazilian Semaglutide Competition Hots Up With Sandoz-Adalvo Approval
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Generics Bulletin - July 29, 2026

Generics Bulletin’s Top 50 Ranking For 2026
This article compiles all the data from Generics Bulletin’s 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms’ financial figures compare.
Generics Bulletin - July 29, 2026

The Generics Bulletin Top 50, Part Three: Industry Evolution Opens Door To New Players
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026

Pharma Is Spending More To Launch Less, And Scale Is No Longer The Answer
Norstella's new Pipeline-to-Patient Productivity Index finds R&D spend rising as output falls, yet the biggest spenders are not the winners. Beneath a GLP-1-inflated launch boom sits a portfolio-rejuvenation gap that could hollow out top-25 revenues by 2030.
In Vivo - July 30, 2026